Allergan and Gedeon Richter Announce Positive Phase III Resu
Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with abnormal bleeding due to uterine fibroids. A new drug application filing for ulipristal acetate is planned for the second half of 2017.


"We are pleased with the favorable results of Venus II supporting the efficacy and safety profile of ulipristal acetate as shown in our Venus I trial," said David Nicholson, Chief Research and Development Officer, Allergan. "Allergan is committed to identifying, developing and bringing to market therapies that address unmet need and provide significant value to the healthcare system, including a potential new treatment for symptomatic uterine fibroids. We are confident that the results of our phase III trials for ulipristal acetate may potentially offer the first and only oral treatment option for women suffering from uterine fibroids in the U.S."...

https://www.drugs.com/clinical_trials/allergan-gedeon-richter-announce-positive-phase-iii-results-ulipristal-acetate-5-10-mg-uterine-17319.html
Like
Comment
Share